BiondVax Pharmaceuticals

162 articles with BiondVax Pharmaceuticals

• BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Business Update

  11/24/2021

  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), reports that the Annual General Meeting (AGM) of Shareholders of the Company will be held on December 27, 2021 in Tel Aviv, Israel.

• BiondVax to Present at H.C. Wainwright 7th Annual Israel Conference

  11/15/2021

  BiondVax Pharmaceuticals Ltd. announced that Chief Executive Officer Amir Reichman will present a company overview at the H.C. Wainwright 7th Annual Israel Virtual Conference Nov. 15, 2021 at 10:30 am ET.

• BiondVax advances its growth strategy towards a new pipeline based on innovative VHH antibodies

  10/19/2021

  BiondVax Pharmaceuticals Ltd., which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced the signing of a term sheet that includes binding financial terms of contemplated definitive agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.

• BiondVax Announces First Quarter 2021 Financial Results and Provides Business Update

  6/23/2021

  BiondVax Pharmaceuticals Ltd., a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, published its first quarter financial results for the quarter ended March 31, 2021.

• BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

  5/13/2021

  BiondVax Pharmaceuticals Ltd., a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, published its fourth quarter and full year financial results for the year ended December 31, 2020 and provided a business update.

• Letter from BiondVax's New CEO to Shareholders

  3/23/2021

  Dear Shareholders, After many years of pharmaceutical leadership positions in the US and Europe , I jumped at the opportunity to return to my roots in Israel to take over the reins as BiondVax's CEO

• BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering

  2/10/2021

  BiondVax Pharmaceuticals Ltd. today announced that the underwriter of its recent follow-on underwritten offering fully exercised its over-allotment option to purchase 365,217 of BiondVax's American Depositary Shares ("ADS").

• BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering

  2/2/2021

  BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced the closing of its previously announced underwritten offering.

• BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares

  1/28/2021

  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced its intention to offer its American Depositary Shares ("ADSs") in an underwritten public offering

• BiondVax Announces Third Quarter 2020 Financial Results & Business Update

  1/28/2021

  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced its third quarter financial results for the quarter ended September 30, 2020.

• BiondVax Announces Appointment of Amir Reichman as New CEO

  1/21/2021

  Pharma Industry Veteran in Vaccines will Assume Role Full Time March 2, 2021, with Focus on Developing Product Pipeline in Infectious Diseases

• BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate

  10/23/2020

  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide protection against current, future, seasonal and pandemic influenza, today announced topline data from the Company's pivotal, phase 3 clinical trial of M-001 as a standalone universal flu vaccine candidate.  

• /C O R R E C T I O N -- BiondVax Pharmaceuticals Ltd./

  10/23/2020

  In the news release, BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate, issued Oct. 23, 2020 by BiondVax Pharmaceuticals Ltd. over PR Newswire, we are advised by the company that the Forward Looking Statements were not included. The complete, corrected release follows: BiondVax Announces Topline Results from P

• BiondVax Announces Second Quarter 2020 Financial Results

  8/20/2020

  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its second quarter financial results for the quarter ended June 30, 2020 .

• BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update

  8/13/2020

   BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M–001 universal influenza vaccine candidate, today announced that the Annual General Meeting of Shareholders of the Company will be held on September 2, 2020 in Tel Aviv, Israel . Details, including a link to the Proxy Statement and voting card, ar

• Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

  7/1/2020

  BiondVax Pharmaceuticals Ltd. announced that all participants in the placebo-controlled, blinded, pivotal, clinical efficacy, Phase 3 trial of BiondVax's M–001 universal influenza vaccine candidate have now completed their site visits.

• BiondVax Announces First Quarter 2020 Financial Results

  6/30/2020

  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its first quarter financial results for the quarter ended March 31, 2020.

• BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

  6/12/2020

  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its fourth quarter and full year financial results for the year ended December 31, 2019 and provided a business update.

• NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved

  6/10/2020

  BiondVax Pharmaceuticals Ltd. announced the completion of the clinical study report of a Phase 2 clinical trial of the Company's M-001 universal influenza vaccine candidate.

• BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants

  5/20/2020

  BiondVax Pharmaceuticals Ltd., developer of the M‑001 universal influenza vaccine candidate, announced receipt of proceeds of approximately $4.2 million since January 1, 2020 through exercises of BiondVax warrants.